Liminal BioSciences Inc.
LMNL · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -37.6% | -80.6% | -32.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 38.7% | 43.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,943.9% | -7,031.6% | -3,170.5% | -4,093.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,211% | -7,008.2% | -3,682.2% | -4,776.2% |
| EPS Diluted | -9.32 | -14.94 | -49.97 | -145.82 |
| % Growth | 37.6% | 70.1% | 65.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |